The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI
Last

(U.S.) $0.93

Today's change-0.09 -8.82%
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI
Last

(U.S.) $0.93

Today's change-0.09 -8.82%
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.

OncoGenex Pharmaceuticals Inc crosses below 50-day moving average

OncoGenex Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.09 or 8.82% to (U.S.)$0.93 and crossing below its 50-day moving average. Over the last five days, shares have lost 13.89% and are down 23.14% for the last year to date. This security has underperformed the S&P 500 by 60.30% during the last year.

Key company metrics

  • Open(U.S.) $1.00
  • Previous close(U.S.) $1.02
  • High(U.S.) $1.02
  • Low(U.S.) $0.93
  • Bid / Ask(U.S.) $0.90 / (U.S.) $1.35
  • YTD % change-23.14%
  • Volume450,023
  • Average volume (10-day)294,255
  • Average volume (1-month)406,661
  • Average volume (3-month)461,184
  • 52-week range(U.S.) $0.46 to (U.S.) $4.10
  • Beta1.85
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.60
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX1.69%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue3674
Total other revenue--------
Total revenue3674
Gross profit--------
Total cost of revenue--------
Total operating expense7101110
Selling / general / administrative2333
Research & development5787
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0------
Other operating expenses, total--------
Operating income-4-3-5-6
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-4-2-5-6
Income after tax-4-2-5-6
Income tax, total--------
Net income-4-2-5-6
Total adjustments to net income--------
Net income before extra. items-4-2-5-6
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-4-2-5-6
Inc. avail. to common incl. extra. items-4-2-5-6
Diluted net income-4-2-5-6
Dilution adjustment--------
Diluted weighted average shares30302923
Diluted EPS excluding extraordinary itemsvalue per share-0.12-0.06-0.16-0.26
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.11-0.06-0.16-0.26